Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) is a clinical-stage immunology-based biopharmaceutical company, and its news flow reflects the progress and risks of drug development in inflammatory and immunological diseases. Company announcements routinely describe advances in its pipeline, particularly its anti-IgE monoclonal antibody program ozureprubart (formerly RPT904), as well as financial updates and investor outreach activities.
Visitors to this news page can review press releases on key clinical milestones, such as FDA clearance of an Investigational New Drug application, initiation of the prestIgE Phase 2b trial of ozureprubart in IgE-mediated food allergy, and positive topline data from a Phase 2 trial in chronic spontaneous urticaria conducted by partner Shanghai Jeyou Pharmaceutical Co., Ltd. RAPT’s news also highlights how these data compare to existing therapies like omalizumab in terms of dosing intervals and measured endpoints within the reported studies.
RAPT frequently reports quarterly financial results, detailing research and development and general and administrative expenses, net losses and cash, cash equivalents and marketable securities. News items also cover capital-raising events, such as the pricing and completion of underwritten public offerings of common stock, and the company’s estimates regarding how long its capital resources may fund operations based on current plans.
In addition, RAPT issues press releases about participation in healthcare and investor conferences, including major events hosted by firms such as J.P. Morgan, Wells Fargo, Guggenheim, Stifel, TD Cowen, Cantor and H.C. Wainwright. These updates indicate when management will present company overviews or fireside chats and how investors can access related webcasts or archived presentations.
For investors and observers following RAPT, this news feed provides a consolidated view of clinical trial developments, regulatory interactions, financial disclosures and corporate events that shape the company’s progress in developing therapies for inflammatory and immunological diseases.
RAPT Therapeutics (RAPT) announced promising initial results from its Phase 1/2 trial of FLX475, highlighting monotherapy activity and efficacy in combination with pembrolizumab. The trial includes multiple cancer types, with favorable safety data and biomarker support for FLX475’s mechanism. RAPT plans to advance three cancer indications—EBV+ lymphoma, nasopharyngeal cancer, and head and neck cancer—into Phase 2 expansions based on early efficacy data. The company continues patient enrollment and anticipates further updates in the upcoming year.
RAPT Therapeutics announced plans to present initial data from its Phase 1/2 clinical trial of FLX475 for multiple cancer indications on November 16, 2020. The conference call will occur at 8:30 a.m. ET, and a live webcast will be available on the company's website. RAPT focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases. Their drug candidates target key immune drivers, including CCR4. This data release is expected to provide insights into the efficacy and potential market impact of FLX475.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that President and CEO Brian Wong will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 4:00 p.m. ET. The event will be accessible via a live webcast on the RAPT Therapeutics website. The company focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases. RAPT has advanced drug candidates FLX475 and RPT193, targeting CCR4, along with other developmental targets including HPK1 and GCN2.
RAPT Therapeutics (RAPT) announced the addition of renowned oncology experts Lisa Butterfield, Ph.D. and Lawrence Fong, M.D. to its Scientific Advisory Board. Dr. Butterfield is noted for her work in cancer immunotherapy, while Dr. Fong specializes in various cancers and immunotherapy development. Both will contribute critical insights to advance RAPT's clinical programs, specifically FLX475. Their expertise could enhance the company's efforts in oral small molecule therapies targeting significant unmet needs in oncology and inflammatory diseases.
RAPT Therapeutics reported a net loss of $12.4 million for Q2 2020, up from $10.6 million in Q2 2019. R&D expenses rose to $11.0 million due to clinical costs for FLX475 and RPT193, with G&A expenses slightly increasing to $2.8 million. For the six-month period, net loss was $25.5 million, compared to $19.8 million in 2019, with R&D expenses reaching $21.7 million. As of June 30, 2020, the company held cash and marketable securities worth $133.0 million. RAPT remains on track to report key clinical trial results by year-end.
RAPT Therapeutics (Nasdaq: RAPT) has appointed Peter Svennilson to its Board of Directors, replacing David Goeddel, who opted not to seek reelection. Svennilson, Managing Partner at The Column Group, has been involved with RAPT for several years and will provide strategic insights and guidance. His appointment comes as RAPT anticipates proof-of-concept data for its drug candidates, FLX475 and RPT193, expected within the year. RAPT focuses on developing small molecule therapies to address significant unmet needs in oncology and inflammatory diseases.
RAPT Therapeutics reported its Q1 2020 financial results, showing a net loss of $13.1 million, up from $9.2 million in Q1 2019. Revenue reached $0.9 million, tied to a collaboration with Hanmi Pharmaceutical, compared to no revenue in Q1 2019. R&D expenses rose to $10.7 million due to advancing clinical trials, while G&A expenses increased to $3.3 million largely due to stock-based compensation and legal fees. As of March 31, 2020, RAPT had $138.2 million in cash and equivalents, bolstered by $69.8 million from a follow-on public offering.